Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Терапия хронической обструктивной болезни легких: возможности индакатерола
Терапия хронической обструктивной болезни легких: возможности индакатерола
Княжеская Н.П. Терапия хронической обструктивной болезни легких: возможности индакатерола. Consilium Medicum. 2014; 16 (11): 13–17.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Число пациентов, страдающих хронической обструктивной болезнью легких (ХОБЛ), значительно выше, чем зарегистрировано в лечебных учреждениях. Поздняя диагностика ХОБЛ – одна из актуальных проблем, так как при ранних стадиях болезни пациенты долгое время считают себя здоровыми людьми, а ее симптомы (кашель, отделение мокроты и появление одышки при физической нагрузке) объясняют другими причинами. Следует подчеркнуть, что ХОБЛ является не только большой медицинской проблемой, но и крайне сложной социальной проблемой, заключающейся в высокой степени социальной дезадаптации пациентов преимущественно пожилого возраста. Одно из центральных мест в фармакотерапии ХОБЛ занимают бронхолитики, применение которых позволяет уменьшить выраженность одышки и увеличить толерантность к физической нагрузке. В настоящее время в клинической практике стал широко применяться представитель класса b2-агонистов с быстрым и ультрадлительным (24-часовым) действием – индакатерол (Онбрез® Бризхалер®). Важной особенностью препарата является высокая кардиобезопасность. Применение препарата Онбрез® Бризхалер® позволит снизить количество обострений, увеличить толерантность к физической нагрузке, повысить качество жизни пациентов с ХОБЛ.
Ключевые слова: хроническая обструктивная болезнь легких, толерантность к физической нагрузке, гиперинфляция, индакатерол, интервал QT, b2-агонисты ультрадлительного действия.
Key words: COPD, exercise tolerance, hyperinflation, indacaterol, interval QT, βb2-agonists, ultra-long-acting.
Ключевые слова: хроническая обструктивная болезнь легких, толерантность к физической нагрузке, гиперинфляция, индакатерол, интервал QT, b2-агонисты ультрадлительного действия.
________________________________________________
Key words: COPD, exercise tolerance, hyperinflation, indacaterol, interval QT, βb2-agonists, ultra-long-acting.
Полный текст
Список литературы
1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. http://www.goldcopd.org/
2. European Lung Foundation. COPD Burden in Europe. 2009 www.european-lung-foundation.org
3. Lopez AD, Shibuya K, Rao C et al. Chronic Obstructive Lung Disease: current burden and future projections. Eur Respir J 2006; 27 (1): 188–207.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349 (9064): 1498–504.
5. Респираторная медицина. Руководство. Под ред. А.Г.Чучалина. М.: ГЭОТАР-Медиа, 2007.
6. Anthonisen NR, Connett JE, Murray RP and The Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–9.
7. Чучалин А.Г. Система оксиданты и антиоксиданты и пути коррекции. Пульмонология. 2004; 4: 111–5.
8. Соодаева С.К. Роль свободнорадикального окисления в патогенезе ХОБЛ. Атмосфера. Пульмонология и аллергология. 2000; 5: 27–31.
9. Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013; 22 (1): 101–11.
10. Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med 2006; 119: 32–7.
11. Waschki B, Kirsten A, Holz O et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140 (2): 331–42.
12. Rytila P, Rehn T, Ilumets H et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006; 28 (7): 69.
13. Dellacà RL, Pompilio PP, Walker PP et al. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J 2009; 33 (6): 1329–37.
14. Thomas M et al. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013; 22 (1): 101–11; Rossi review 2014.
15. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: astatement of the American Thoracic Society and European Respiratory Society. American Thoracic Society, European Respiratory Society. Am J Respir Crit Care Med 1998; 158: 629–34.
16. Naline E, Trifilieff A, Fairhurst RA et al. Effect of indacaterol, a novel long-acting b2-adrenoceptor agonist, on human isolated bronchi. Eur Respir J 2007; 29: 575–81.
17. Battram C, Charlton SJ, Cuenoud B et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled b2-adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762–70.
18. Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ. Pharmacological characterization of indacaterol, a novel once daily inhaled b2-adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008; 324: 270–5.
19. Mihăltan F. Indacaterol – a new hope for maximising bronchodilation? Pneumologia 2011; 60 (1): 21–5.
20. Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009; 38 (5): 533–47.
21. Beeh KM, Beier J. The short, the long and the «ultra-long»: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010; 27 (3): 150–9.
22. Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150 mg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11.
23. Kornmann O, Dahl R, Centanni S et al. INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD:
a placebo-controlled comparison. Eur Respir J 2011; 37 (2): 273–9.
24. Dahl R, Chung K F, Buhl R et al. On behalf of the INVOLVE Study Investigators. Efficacy of a new once-daily, long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473–9.
25. Donohue JF, Fogarty C, Lötvall J et al. INHANCE Study Investigators.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182 (2): 155–62.
26. O’Donnell DE, Casaburi R, Vincken W et al. INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011; 105 (7): 1030–6.
27. Watz H, Krippner F, Kirsten A et al. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease – a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med 2014; 14: 158.
28. Rennard S, Bantje T, Centanni S et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102: 1033–44.
29. Khindri S, Sabo R, Harris S et al. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 2011; 26 (11): 31.
30. Milic M, Bao X, Rizos D et al. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation. Clin Ther 2006; 28: 582–90.
31. Worth H, Chung KF, Felser JM et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105: 571–9.
32. Pascoe S, Reynolds C, Pleskow W et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily b2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther 2011; 49: 153–61.
33. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043–8.
34. Partridge MR, Schuermann W, Beckman O et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3: 1–11.
35. Wedzicha JA, Dahl R, Buhl R et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014; 108 (10): 1498–507.
2. European Lung Foundation. COPD Burden in Europe. 2009 www.european-lung-foundation.org
3. Lopez AD, Shibuya K, Rao C et al. Chronic Obstructive Lung Disease: current burden and future projections. Eur Respir J 2006; 27 (1): 188–207.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349 (9064): 1498–504.
5. Респираторная медицина. Руководство. Под ред. А.Г.Чучалина. М.: ГЭОТАР-Медиа, 2007.
6. Anthonisen NR, Connett JE, Murray RP and The Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–9.
7. Чучалин А.Г. Система оксиданты и антиоксиданты и пути коррекции. Пульмонология. 2004; 4: 111–5.
8. Соодаева С.К. Роль свободнорадикального окисления в патогенезе ХОБЛ. Атмосфера. Пульмонология и аллергология. 2000; 5: 27–31.
9. Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013; 22 (1): 101–11.
10. Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med 2006; 119: 32–7.
11. Waschki B, Kirsten A, Holz O et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140 (2): 331–42.
12. Rytila P, Rehn T, Ilumets H et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006; 28 (7): 69.
13. Dellacà RL, Pompilio PP, Walker PP et al. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J 2009; 33 (6): 1329–37.
14. Thomas M et al. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013; 22 (1): 101–11; Rossi review 2014.
15. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: astatement of the American Thoracic Society and European Respiratory Society. American Thoracic Society, European Respiratory Society. Am J Respir Crit Care Med 1998; 158: 629–34.
16. Naline E, Trifilieff A, Fairhurst RA et al. Effect of indacaterol, a novel long-acting b2-adrenoceptor agonist, on human isolated bronchi. Eur Respir J 2007; 29: 575–81.
17. Battram C, Charlton SJ, Cuenoud B et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled b2-adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762–70.
18. Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ. Pharmacological characterization of indacaterol, a novel once daily inhaled b2-adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008; 324: 270–5.
19. Mihăltan F. Indacaterol – a new hope for maximising bronchodilation? Pneumologia 2011; 60 (1): 21–5.
20. Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009; 38 (5): 533–47.
21. Beeh KM, Beier J. The short, the long and the «ultra-long»: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010; 27 (3): 150–9.
22. Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150 mg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11.
23. Kornmann O, Dahl R, Centanni S et al. INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD:
a placebo-controlled comparison. Eur Respir J 2011; 37 (2): 273–9.
24. Dahl R, Chung K F, Buhl R et al. On behalf of the INVOLVE Study Investigators. Efficacy of a new once-daily, long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473–9.
25. Donohue JF, Fogarty C, Lötvall J et al. INHANCE Study Investigators.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182 (2): 155–62.
26. O’Donnell DE, Casaburi R, Vincken W et al. INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011; 105 (7): 1030–6.
27. Watz H, Krippner F, Kirsten A et al. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease – a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med 2014; 14: 158.
28. Rennard S, Bantje T, Centanni S et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102: 1033–44.
29. Khindri S, Sabo R, Harris S et al. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 2011; 26 (11): 31.
30. Milic M, Bao X, Rizos D et al. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation. Clin Ther 2006; 28: 582–90.
31. Worth H, Chung KF, Felser JM et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105: 571–9.
32. Pascoe S, Reynolds C, Pleskow W et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily b2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther 2011; 49: 153–61.
33. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043–8.
34. Partridge MR, Schuermann W, Beckman O et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3: 1–11.
35. Wedzicha JA, Dahl R, Buhl R et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014; 108 (10): 1498–507.
Авторы
Н.П.Княжеская
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.